No Data
No Data
Tengshengbo Pharmaceuticals made its first appearance at the 2024 American Association for the Study of Liver Diseases (AASLD) annual meeting to release the results of the combination of siRNA (Elebsiran) with PEG-IFNα compared to monotherapy with PEG-IFN
The 48-week treatment data from the ongoing Phase 2 ENSURE study clearly indicates that the combination of elebsiran and PEG-IFNα can provide more benefits, resulting in a higher functional cure rate. Multiple combination study data conducted by the company and its partners will continue to support the company's strategy of achieving functional HBV cure in a broader patient population through the correct combination treatment plan. Peking, china and Durham, north carolina, usa, November 19, 2024 /PRNewswire/ -- Tengsheng Bo Pharmaceutical Biotechnology Co., Ltd. ("Tengsheng Bo Pharmaceutical" or "the company",
At the 2024 EASL conference, Tengshengbo Medicine released the latest data from its ongoing Phase 2 study of chronic hepatitis B.
New conversion data shows that BRII-179 induced immune response is closely related to the significant decrease of hepatitis B surface antigen (HBsAg) in some chronic hepatitis B virus (HBV) infected subjects. BRII-179 as add-on therapy can induce functional antibody response and help improve HBsAg sustained clearance in chronic HBV infected subjects receiving pegylated interferon alpha (PEG-IFNα) treatment. Peking, China and Durham, North Carolina, USA, June 7, 2024 / PRNewswire / - Tensunbo Biomedical Technology Co.
Based on sufficient clinical evidence from multiple phase 1 and phase 2 studies, the two candidate drugs BRII-877 and BRII-835 of Tengsheng Pharmaceutical were recognized as breakthrough treatment varieties by CDE
Beijing, China and Durham, North Carolina, USA, May 14, 2024/PRNewswire/ -- Tengshengboyao Biotechnology Co., Ltd. (“Tengshengbo Pharmaceutical” or “Company”, stock code: 2137.HK), a multinational enterprise dedicated to developing innovative treatments for patients' unmet needs and major public health diseases, today announced that China's National Drug Administration (NMPA) Drug Evaluation Center (CDE) will be developing a broad-spectrum neutralizing monoclonal antibody BRII-877 ( Tobevibart) and
